New York, February 05, 2016 -- Moody's Investor's Service said that Zimmer Biomet Holdings, Inc.'s (ZBH's) announcement that it will repurchase a portion of the shares being sold by affiliates of Blackstone and Goldman Sachs is viewed as credit negative because the company is in the midst of deleveraging following last June's merger with Biomet. However, this development does not have an effect on ZBH's Baa3 ratings or stable outlook at this time. For additional information, please refer to Moody's Issuer Comment on Zimmer Biomet on www.moodys.com.

Vollständigen Artikel bei Moodys lesen